Cyprus is, according to information from the CYPE, one of the countries participating in the agreement for the joint supply of a new vaccine against the disease COVID-19, which is in the process of being developed as a booster vaccine.
The agreement was signed on Tuesday between the pharmaceutical company HIPRA and the Health Emergency Preparedness and Response Authority (HERA) and concerns 14 EU and European Economic Area countries, according to a relevant announcement by the Commission.
It is a bivalent recombinant protein vaccine that is being developed as a booster dose for already immunized individuals aged 16 years and older, and is under rolling evaluation by the European Medicines Agency (EMA). The vaccine is stored at a refrigerated temperature between 2 and 8°C.
Under the framework agreement, participating countries will be able to purchase up to 250 million doses.
It is recalled that the EU has so far signed contracts for vaccines against the coronavirus with the companies AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, Moderna, Novavax and Valneva, securing approximately 4,2 billion doses according to the Commission's calculations.
As noted, countries participating in the joint supply agreement will be able to donate the vaccines to lower and middle-income countries or redirect them to other European countries.